» Articles » PMID: 33629141

Hemodiafiltration Maintains a Sustained Improvement in Blood Pressure Compared to Conventional Hemodialysis in Children-the HDF, Heart and Height (3H) Study

Abstract

Background: Hypertension is prevalent in children on dialysis and associated with cardiovascular disease. We studied the blood pressure (BP) trends and the evolution of BP over 1 year in children on conventional hemodialysis (HD) vs. hemodiafiltration (HDF).

Methods: This is a post hoc analysis of the "3H - HDF-Hearts-Height" dataset, a multicenter, parallel-arm observational study. Seventy-eight children on HD and 55 on HDF who had three 24-h ambulatory BP monitoring (ABPM) measures over 1 year were included. Mean arterial pressure (MAP) was calculated and hypertension defined as 24-h MAP standard deviation score (SDS) ≥95th percentile.

Results: Poor agreement between pre-dialysis systolic BP-SDS and 24-h MAP was found (mean difference - 0.6; 95% limits of agreement -4.9-3.8). At baseline, 82% on HD and 44% on HDF were hypertensive, with uncontrolled hypertension in 88% vs. 25% respectively; p < 0.001. At 12 months, children on HDF had consistently lower MAP-SDS compared to those on HD (p < 0.001). Over 1-year follow-up, the HD group had mean MAP-SDS increase of +0.98 (95%CI 0.77-1.20; p < 0.0001), whereas the HDF group had a non-significant increase of +0.15 (95%CI -0.10-0.40; p = 0.23). Significant predictors of MAP-SDS were dialysis modality (β = +0.83 [95%CI +0.51 - +1.15] HD vs. HDF, p < 0.0001) and higher inter-dialytic-weight-gain (IDWG)% (β = 0.13 [95%CI 0.06-0.19]; p = 0.0003).

Conclusions: Children on HD had a significant and sustained increase in BP over 1 year compared to a stable BP in those on HDF, despite an equivalent dialysis dose. Higher IDWG% was associated with higher 24-h MAP-SDS in both groups.

Citing Articles

Prospective Study of Modifiable Risk Factors of Arterial Hypertension and Left Ventricular Hypertrophy in Pediatric Patients on Hemodialysis.

Borzych-Duzalka D, Shroff R, Ranchin B, Zhai Y, Paglialonga F, Kari J Kidney Int Rep. 2024; 9(6):1694-1704.

PMID: 38899176 PMC: 11184401. DOI: 10.1016/j.ekir.2024.03.016.


Hemodiafiltration for children with stage 5 chronic kidney disease: technical aspects and outcomes.

Ahlmann C, Stronach L, Waters K, Walker K, Oh J, Peter Schmitt C Pediatr Nephrol. 2024; 39(9):2611-2626.

PMID: 38347283 PMC: 11272808. DOI: 10.1007/s00467-024-06285-w.


The effects of hospital and dialysis unit characteristics on hospitalizations for access-related complications among children on maintenance dialysis: a European, multicenter, observational, cross-sectional study.

Ozdemir Atikel Y, Peter Schmitt C, Levai E, Adalat S, Shroff R, Goodman N Pediatr Nephrol. 2023; 38(7):2189-2198.

PMID: 36595069 DOI: 10.1007/s00467-022-05842-5.

References
1.
Shroff R, Weaver Jr D, Mitsnefes M . Cardiovascular complications in children with chronic kidney disease. Nat Rev Nephrol. 2011; 7(11):642-9. DOI: 10.1038/nrneph.2011.116. View

2.
Kramer A, van Stralen K, Jager K, Schaefer F, Verrina E, Seeman T . Demographics of blood pressure and hypertension in children on renal replacement therapy in Europe. Kidney Int. 2011; 80(10):1092-8. DOI: 10.1038/ki.2011.232. View

3.
de Ferranti S, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly A . Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. Circulation. 2019; 139(13):e603-e634. DOI: 10.1161/CIR.0000000000000618. View

4.
Urbina E, Mendizabal B, Becker R, Daniels S, Falkner B, Hamdani G . Association of Blood Pressure Level With Left Ventricular Mass in Adolescents. Hypertension. 2019; 74(3):590-596. DOI: 10.1161/HYPERTENSIONAHA.119.13027. View

5.
Chesnaye N, Schaefer F, Bonthuis M, Holman R, Baiko S, Baskin E . Mortality risk disparities in children receiving chronic renal replacement therapy for the treatment of end-stage renal disease across Europe: an ESPN-ERA/EDTA registry analysis. Lancet. 2017; 389(10084):2128-2137. DOI: 10.1016/S0140-6736(17)30063-6. View